BIOTRONIK Announces Launch of Next Generation Injectable Cardiac Monitor

Image courtesy of Biotronik.

Register to receive a free U.S. Market Report Suite for Cardiac Rhythm Management Devices – MedSuite report synopsis and brochure

Biotronik is releasing a new version of its popular Biomonitor injectable cardiac monitor. The Biomonitor III is less than half the size of the Biomonitor II, while offering much clearer signal quality. This innovative device was engineered to help patients with irregular heart rhythms by tracking suspected arrhythmia or unexplained syncopes with increased clarity.

It was designed to be injected under the skin, where it continuously monitors and records the patient’s electrical heart signals. Monitoring the patient’s heart signals can help detect cardiac arrhythmias and unexplained syncopes (loss of consciousness). Atrial fibrillation, being one of the greatest culprits in the development of strokes, heart failure, and other conditions, will be the main diagnostic target of the Biomonitor III. The new monitor can significantly increase signal amplitudes and the visibility of p-waves compared with the previous generation of the device, helping cardiologists to better spot arrhythmias.

“What I like about Biomonitor III is the ease of use and the high signal fidelity,” said Associate Professor Paul Gould, cardiologist and electrophysiologist at St Andrew’s War Memorial Hospital, Brisbane, Australia, in a Biotronik press release. “This, coupled with the automatic Home Monitoring, provides an excellent resource to establish a rhythm symptom correlation or to detect occult arrhythmias in my patients.”

According to a series of reports on the Cardiac Rhythm Management market conducted by iData Research, the total market for cardiac rhythm management was valued at over $5 billion. The economic recovery of the U.S. economy over the past several years has led to growth in nearly all markets, with particularly strong growth in the CRT market. These devices are considered to be critical life-saving apparatus, and as a result of the aging U.S. population, market growth is expected to recover.

“We developed Biotronik III to bring an injectable diagnostic solution with clear signal quality to the market,” commented Dr. Alexander Uhl, Senior Vice President Corporate Marketing at Biotronik. “Working with an ICM should be easy, efficient and in-office-friendly – Biotronik III is exactly that. With all its features, our new monitor reliably provides physicians with the needed information in high quality on the patient’s condition to avoid health risks associated with arrhythmia.”


For Further Information

More on the cardiac rhythm management market can be found in a series of reports published by iData entitled the U.S. Market Report Suite for Cardiac Rhythm Management Devices

Leave a Reply